Relationships between plasma β-amyloid peptide 1-42 and atherosclerotic risk factors in community-based older populations

Gerontology

Volumn 49, Issue 6, 2003, Pages 374-379

  Fujiwara, Yoshinori ^a   Takahashi, Makoto ^b   Tanaka, Masaharu ^c   Hoshi, Tanji ^d   Someya, Toshiyuki ^b   Shinkai, Shoji ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c Mishima Hospital   (Japan)

^d TOKYO METROPOLITAN UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Atherosclerotic risk factors; Community; Dementia; Elderly; Plasma amyloid peptide 1 42

Indexed keywords

AMYLOID BETA PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CELL COUNT; COMMUNITY CARE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEALTH SURVEY; HEMATOCRIT; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; SOCIAL PSYCHOLOGY; SYSTOLIC BLOOD PRESSURE;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ARTERIOSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RESIDENCE CHARACTERISTICS; RISK FACTORS; TRIGLYCERIDES;

EID: 0344826525     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073765     Document Type: Article

References (40)

1. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM: RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-691.
2. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, Olson D, Southwick P, Wolfert R, Munroe B, Lieberburg I, Seubert P, Schenk D: Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
3. Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E, Jauss M, Beyreuther K, Lannfelt L, Hartmann T: Cerebrospinal fluid A β42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 1999;45:504-511.
4. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Evaluation of CSF-tau and CSF-Aβ 42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-379.
5. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S: Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870.
6. Katzman R, Aronson M, Fuld P, Kawas C, Brown T, Morgenstern H, Frishman W, Gidez L, Eder H, Ooi WL: Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol 1989;25:317-324.
7. Meyer JS, Rauch GM, Crawford K, Rauch RA, Konno S, Akiyama H, Terayama Y, Haque A: Risk factors accelerating cerebral degenerative changes, cognitive decline and dementia. Int J Geriatr Psychiatry 1999;14:1050-1061.
8. Schmidt R, Schmidt H, Fazekas F: Vascular risk factors in dementia. J Neurol 2000;247:81-87.
9. Kondo K, Niino M, Shido K: A case-control study of Alzheimer's disease in Japan - Significance of life-styles. Dementia 1994;5:314-326.
10. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW: Studies of illness in the aged: The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963;185:914-919.
11. Koyano W, Shibata H, Nakazato K, Haga H, Suyama Y: Measurement of competence: Reliability and validity of the TMIG-Index of Competence. Arch Gerontol Geriatr 1991;13:103-116.
12. Ishizaki T, Watanabe S, Suzuki T, Shibata H, Haga H: Predictors for functional decline among nondisabled older Japanese living in a community during a 3-year follow-up. J Am Geriatr Soc 2000;48:1424-1429.
13. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-154.
14. Breteler MM, Claus JJ, Grobbee DE, Hofman A: Cardiovascular disease and distribution of cognitive function in elderly people: The Rotterdam Study. BMJ 1994;308:1604-1608.
15. Brayne C, Gill C, Huppert FA, Barkley C, Gehlhaar E, Girling DM, O'Connor DW, Paykel ES: Vascular risks and incident dementia: Results from a cohort study of the very old. Dement Geriatr Cogn Disord 1998;9:175-180.
16. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease: The Nun Study. JAMA 1997;277:813-817.
17. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A: 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145.
18. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Nomiyama K, Kawano H, Ueda K, Sueishi K, Tsuneyoshi M, Fujishima M: Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study. Neurology 1995;45:1161-1168.
19. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM: Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia 1996;39:1392-1397.
20. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999;53:1937-1942.
21. Strachan MW, Deary IJ, Ewing FM, Frier BM: Is type II diabetes associated with an increased risk of cognitive dysfunction? Diabetes Care 1997;20:438-445.
22. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 2001;322:1447-1451.
23. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA: Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000;7:321-331.
24. Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, Gross DR: Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994;126:88-94.
25. Reaven GM, Thompson LW, Nahum D, Haskins E: Relationship between hyperglycemia and cognitive function in older NIDDM patients. Diabetes Care 1990;13:16-21.
26. Frolich L, Blum-Degen D, Riederer P, Hoyer S: A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann NY Acad Sci 1999;893:290-293.
27. Streit WJ, Sparks DL: Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J Mol Med 1997;75:130-138.
28. Barger SW, Harmon AD: Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997;388:878-881.
29. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M: Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999;286:2352-2355.
30. Suo Z, Tan J, Placzek A, Crawford F, Fang C, Mullan M: Alzheimer's beta-amyloid peptides include inflammatory cascade in human vascular cells: The roles of cytokines and CD40. Brain Res 1998;807:110-117.
31. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD: Plasma amyloid β-peptide1-42 and incipient Alzheimer's disease. Ann Neurol 1999;46:412-416.
32. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L: Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397-405.
33. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 2001;56:1683-1689.
34. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment. Arch Neurol 1999;56:303-308.
35. Mathew NT, Meyer JS, Achari AN, Dodson RF: Hyperlipidemic neuropathy and dementia. Eur Neurol 1976;14:370-382.
36. Mas JL, Bousser MG, Lacombe C, Agar N: Hyperlipidemic dementia. Neurology 1985;35:1385-1387.
37. Rogers RL, Meyer JS, McClintic K, Mortel KF: Reducing hypertriglyceridemia in elderly patients with cerebrovascular disease stabilizes or improves cognition and cerebral perfusion. Angiology 1989;40:260-269.
38. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-6464.
39. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M: Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 1999;45:537-541.
40. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB: Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: A case-control study. Neurology 1995;45:1092-1096.